Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03139331 · ClinicalTrials.gov registry record · Phase 1
PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03139331 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 16 participants.
The verdict
NCT03139331, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is the first study to evaluate the safety and clinical activity of the combination of oral pazopanib, intravenous or oral irinotecan, and oral temozolomide in pediatric and young adult patients with relapsed or refractory sarcomas. This study will use a 3 + 3 design for dose escalation (Part 1), followed by an expansion cohort (Part 2) at the recommended phase 2 dose level.
Interventions
- DRUG Temozolomide
- DRUG Irinotecan
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-06-06 |
| Est. Completion | 2020-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03139331
The ClinicalTrials.gov registry entry for NCT03139331 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT03139331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03139331 about?
NCT03139331 is a clinical study titled "PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma". This is the first study to evaluate the safety and clinical activity of the combination of oral pazopanib, intravenous or oral irinotecan, and oral temozolomide in pediatric and young adult patients with relapsed or refractory sarcomas. This study will use a 3 + 3 design for dose escalation (Part 1)...
What is the current status of trial NCT03139331?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-06-06. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT03139331?
The interventions under investigation include: Temozolomide (DRUG), Irinotecan (DRUG), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT03139331?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.